IPO Year: 2020
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
DEF 14A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
10-Q - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
PRE 14A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
10-Q/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
10-K/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)
Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.
15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately. Mr. Cogley brings 15 years of accounting and finance experience to Coeptis, having previously held positions of increasing authority at two "Big 4" accounting firms and served on the management teams of multiple companies in diverse in
Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generat
Study results demonstrate the safety and feasibility of adoptive immunotherapy using allogeneic off-the-shelf NK cells in hospitalized patients with COVID at high risk for progression of disease DVX201, the first allogeneic NK cell therapy derived from pooled donor cord blood CD34+ cells, was administered to 9 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxicities WEXFORD, Pa., Nov. 7, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that results from their Phase 1 st
WEXFORD, Pa., Oct. 24, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced the expansion of its license agreement with Deverra Therapeutics Inc. ("Deverra"), broadening the potential applications of its allogeneic natural killer (NK) cell technology. This expansion includes the use of unmodified NK cells in treating viral infections, pandemic-related illnesses, and emergency stockpiling for future health crises.
WEXFORD, Pa., Oct. 15, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced that its Chief Scientific and Medical Officer Colleen Delaney, MD will attend and present at the following upcoming fall conferences. These events, including the 2024 AABB Annual Meeting, the 50th ASHI Annual Meeting, the Advanced Therapies USA Congress, and the Donor Selection & Cell Source Summit, offer an opportunity to expand awareness of Coeptis' advancements in universal cell therapy and its potential to transform patient outcomes.
WEXFORD, Pa., Sept. 19, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced today that it has received a notification letter from the Nasdaq Hearings Panel (the "Panel") granting its request for continued listing on The Nasdaq Stock Market ("Nasdaq") through January 15, 2025, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(a)(2). As previously disclosed, on January 29,
WEXFORD, Pa., Sept. 5, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today issued a shareholder letter from its Chief Executive Officer Dave Mehalick. Dear Coeptis Therapeutics Shareholders, As summer comes to a close, I am pleased to share with you the latest updates and accomplishments at Coeptis Therapeutics. For the scien
Bolsters Company's Corporate Mission Financing Led by Board Member and Priced at Premium to Market Price WEXFORD, Pa., June 20, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that it has closed on $4.3 million in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise. Under the terms of the financing, the Series A Preferred is convertible i
WEXFORD, Pa., May 30, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that Dr. Colleen Delaney will be attending and presenting at the Allogeneic Cell Therapies Summit 6th Annual Meeting from June 10-12 in Boston, MA. Dr. Colleen Delaney, Chief Scientific and Medical Officer for Coeptis Therapeutics will be delivering two seminars regarding allogeneic products' starting materials. Seminar
WEXFORD, Pa., May 8, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced today that the Company has been selected for an oral presentation of the abstract titled Developing A First-In-Class Universal Allogeneic Snap-Car NK Cell Therapy at the International Society for Cell & Gene Therapy 2024, being held May 28th to June 1st in Vancouver, Canada. The Company's SNAP-CAR platform technology has demons
WEXFORD, Pa., May 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that the Company's abstract for development of SNAP-CAR NK cells will be featured as a poster presentation at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, being held virtually and in-person in Baltimore, MD on May 7-11, 2024. Dr. Carrie Stoltzman, Director of Cell Biology at Deverra Th
WEXFORD, Pa., April 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, is pleased to acknowledge and congratulate Professor Alexander Deiters, on receiving the University of Pittsburgh's 2024 Chancellor's Distinguished Research Award. This prestigious award honors outstanding individuals whose scholarly commitments and contributions to research have significantly advanced their respective fields. Deiters co-developed a CAR T cell therapy platform called "SNAP-CAR" that is based on covalent modification of a universal receptor with adaptor molecules that ta
Gainers Mustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 30.78% to $5.99. The market value of their outstanding shares is at $29.3 million. Rezolute (NASDAQ:RZLT) shares rose 25.0% to $3.75. The company's market cap stands at $150.5 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 16.26% to $1.0. The market value of their outstanding shares is at $146.6 million. Coeptis Therapeutics (NASDAQ:COEP) shares increased by 15.72% to $0.39. The company's market cap stands at $14.4 million. Qilian Intl Hldg Gr
Gainers Orgenesis (NASDAQ:ORGS) shares increased by 8.5% to $0.63 during Thursday's after-market session. The company's market cap stands at $21.4 million. AN2 Therapeutics (NASDAQ:ANTX) shares increased by 6.76% to $3.47. The company's market cap stands at $103.3 million. GRI Bio (NASDAQ:GRI) stock increased by 6.65% to $0.54. NuCana (NASDAQ:NCNA) shares rose 5.92% to $0.25. The market value of their outstanding shares is at $13.4 million. Stoke Therapeutics (NASDAQ:STOK) shares increased by 5.42% to $12.83. The company's market cap stands at $594.0 million. Candel Therapeutics (NASDAQ:CADL) stock moved upwards by 4.99% to $6.72. The market value of their outstanding shares is at $197
Gainers Apollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. Cara Therapeutics (NASDAQ:CARA) shares moved upwards by 7.36% to $0.78. The company's market cap stands at $42.8 million. Coeptis Therapeutics (NASDAQ:COEP) shares moved upwards by 6.66% to $0.32. The company's market cap stands at $10.9 million. Titan Pharma (NASDAQ:TTNP) shares rose 6.44% to $7.75. The market value of their outstanding shares is at $5.8 million. BioSig Technologies (NASDAQ:BSGM) shares increased by 6.38% to $0.5. The market value of their outstanding shares is at $4.6 million. Iridex (NASDAQ:IRIX) stock in
Gainers Geron (NASDAQ:GERN) stock increased by 90.8% to $3.34 during Thursday's after-market session. The market value of their outstanding shares is at $1.8 billion. Madrigal Pharmaceuticals (NASDAQ:MDGL) stock rose 23.16% to $300.0. The market value of their outstanding shares is at $5.9 billion. DIH Holding US (NASDAQ:DHAI) shares rose 10.37% to $1.17. The company's market cap stands at $47.4 million. Synaptogenix (NASDAQ:SNPX) stock increased by 8.33% to $0.2. The company's market cap stands at $3.9 million. Revelation Biosciences (NASDAQ:REVB) shares increased by 8.05% to $2.55. The market value of their outstanding shares is at $1.0 million. Akebia Therapeutics (NASDAQ:AKBA) stoc
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications.
Gainers BioSig Technologies (NASDAQ:BSGM) stock increased by 7.7% to $0.96 during Monday's after-market session. The company's market cap stands at $8.9 million. Coeptis Therapeutics (NASDAQ:COEP) shares rose 6.64% to $0.48. The market value of their outstanding shares is at $16.3 million. Alzamend Neuro (NASDAQ:ALZN) stock rose 6.56% to $0.97. The market value of their outstanding shares is at $6.4 million. China Pharma Holding (AMEX:CPHI) stock increased by 5.7% to $0.1. The company's market cap stands at $5.3 million. AIM ImmunoTech (AMEX:AIM) shares rose 5.54% to $0.45. The market value of their outstanding shares is at $21.9 million. Better Therapeutics (NASDAQ:BTTX) stock moved u
Gainers Xilio Therapeutics (NASDAQ:XLO) shares rose 10.5% to $0.66 during Thursday's after-market session. The market value of their outstanding shares is at $18.2 million. Sensus Healthcare (NASDAQ:SRTS) stock increased by 9.58% to $4.0. The company's market cap stands at $65.5 million. The company's, Q4 earnings came out today. Corvus Pharma (NASDAQ:CRVS) stock moved upwards by 8.49% to $2.17. The market value of their outstanding shares is at $106.4 million. SenesTech (NASDAQ:SNES) shares moved upwards by 6.86% to $1.09. Coeptis Therapeutics (NASDAQ:COEP) stock rose 6.2% to $0.51. The company's market cap stands at $17.3 million. Bright Green (NASDAQ:BGXX) shares moved upwards by 4.
The Dow Jones index closed lower by around 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. OPKO Health The Trade: OPKO Health, Inc. (NASDAQ:OPK) Vice Chairman and CTO PH Jane Hsiao acquired a total of 150,000 shares an average price of $0.95. To acquire these shares, it cost around $142,500. What’s Happening: OPKO Health recently p